Andra AP fonden reduced its stake in shares of Humana Inc. (NYSE:HUM) by 3.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,529 shares of the insurance provider’s stock after selling 1,171 shares during the quarter. Andra AP fonden’s holdings in Humana were worth $9,143,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of HUM. Reliance Trust Co. of Delaware boosted its position in Humana by 0.7% during the 2nd quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock worth $270,000 after acquiring an additional 8 shares during the period. Creative Planning boosted its position in Humana by 0.3% during the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after acquiring an additional 15 shares during the period. WFG Advisors LP boosted its position in Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after acquiring an additional 20 shares during the period. Cadence Capital Management LLC boosted its position in Humana by 0.4% during the 2nd quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock worth $1,367,000 after acquiring an additional 22 shares during the period. Finally, Sit Investment Associates Inc. boosted its position in Humana by 0.3% during the 2nd quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after acquiring an additional 40 shares during the period. Hedge funds and other institutional investors own 95.79% of the company’s stock.
Humana Inc. (NYSE HUM) traded up $1.21 during trading hours on Friday, reaching $256.69. The company had a trading volume of 688,568 shares, compared to its average volume of 1,040,000. The firm has a market capitalization of $37.10 billion, a price-to-earnings ratio of 22.27, a price-to-earnings-growth ratio of 1.66 and a beta of 0.90. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.39. Humana Inc. has a 52-week low of $165.52 and a 52-week high of $264.56.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same quarter last year, the firm posted $2.30 EPS. sell-side analysts anticipate that Humana Inc. will post 11.57 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is 13.06%.
In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the transaction, the insider now owns 18,042 shares of the company’s stock, valued at approximately $4,672,878. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the transaction, the vice president now directly owns 8,831 shares in the company, valued at approximately $2,279,634.34. The disclosure for this sale can be found here. Insiders have sold a total of 55,595 shares of company stock worth $14,133,706 in the last three months. Insiders own 0.80% of the company’s stock.
A number of research analysts have issued reports on the company. Credit Suisse Group assumed coverage on Humana in a research report on Thursday. They set a “neutral” rating and a $256.00 price target for the company. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. BMO Capital Markets assumed coverage on Humana in a research report on Monday, October 16th. They set an “outperform” rating and a $300.00 price target for the company. Jefferies Group LLC reiterated a “hold” rating and set a $257.00 price target on shares of Humana in a research report on Friday, October 13th. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $245.00 price objective on shares of Humana in a report on Tuesday, October 10th. Thirteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Humana presently has a consensus rating of “Hold” and an average price target of $253.71.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
What are top analysts saying about Humana Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana Inc. and related companies.